Introduction
The term non-alcoholic fatty liver disease (NAFLD) refers to the extra fat that accumulates in liver cells, but is not due to excessive alcohol consumption. If a liver's weight is greater than 5-10 % due to fat, it is diagnosed as fatty liver or steatosis. Worldwide, the prevalence of NAFLD is approximately 9-46 %, and an estimated 30 % in the general US population [1] . NAFLD is a spectrum of progressive liver disease that ranges from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), which is the more severe form of fatty liver disease. NASH can progress to cirrhosis and is associated with hepatic failure and hepatocellular carcinoma (HCC) [1] . By 2020, NASH is predicted to become the leading cause of liver transplantation in the US. [2] . NAFLD can also progress to HCC without a prior diagnosis of cirrhosis [3] . In the US, the prevalence of NAFLD and NASH is highest among Latinos, followed by whites and African Americans [4] [5] [6] [7] [8] . Known risk factors for NAFLD and NASH include obesity, metabolic syndrome, diabetes mellitus, and insulin resistance [1, [9] [10] [11] . NAFLD is found in up to 80-90 % of obese adults, in 30-50 % of diabetics, and in up to 90 % of patients with hyperlipidemia [12] . A study of liver disease trends in Mexico indicates that by 2050, 90 % of chronic liver disease cases will be caused by alcohol and/or obesity, with fewer than 10 % of cases due to hepatitis B (HBV) or hepatitis C (HCV) infection [13] .
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are considered reliable tests of liver damage, although NAFLD can also be found in persons with normal liver blood tests [4] . As measures of liver cell injury, ALT and AST levels can help identify asymptomatic liver diseases [14] . Elevated ALT or AST levels may be caused by alcohol, HBV, HCV, NAFLD or NASH [15] . Having elevated ALT or AST levels does not necessarily mean that a person has or will develop liver disease, but cirrhosis and other forms of advanced liver disease can be identified from these tests [5, 16, 17] . Studies have also found that Latinos are more likely to have elevated aminotransferase levels [5, 18, 19] .
There is evidence to support the notion that NAFLD may be a heritable disease, in which the interaction between genetic variants and environmental factors determine the progress and severity of disease [2] . A genomewide association study (GWAS) of 9229 nonsynonymous single-nucleotide polymorphism (SNPs), which was performed as part of the Dallas Heart Study, found that the rs738409 (I148 M) variant in PNPLA3 was strongly associated with liver fat [20] . The prevalence of this SNP was 49 % in Latinos, 23 % in whites, and 17 % in African Americans. The association between the PNPLA3 variant, rs738409 (I148 M), and hepatic fat has been validated [21, 22] and to date it is the most robust and consistent association between hepatic steatosis and a single SNP [23] [24] [25] . The Genetics of Obesity-related Liver Disease Consortium also found variants associated with hepatic steatosis and histologic NAFLD in or near genes NCAN (neurocan), GCKR (glucokinase regulatory protein), LYPLAL1 (lysophospholipase like 1) and PPP1R3B (protein phosphatase 1, regulatory subunit 3b) [21] .
Our primary aim was to perform a candidate gene casecontrol association study to examine nine SNPs located in or near the following genes: PNPLA3, LYPLAL1, PPP1R3B, GCKR, NCAN, IRS1, PPARG, and ADIPOR2 and their association with persistently elevated ALT or AST levels, in 741 adults from Mexico. We chose these specific SNPs based on previous research that has identified variants in or near these genes as potential genetic modifiers that are associated with NAFLD and NASH [21] [22] [23] [24] [25] [26] . PNPLA3, PPP1R3B, and PPARG are believed to affect lipid metabolism [23, 24, 27] , LYPLAL1, GCKR, NCAN, and ADI-POR2 are related to the role of inflammation and development of NAFLD and NASH [23, 24] , while GCKR, IRS1, and PPARG have been linked to insulin resistance [23, 24] . Additionally, SNPs in or near PPP1R3B, GCKR, and NCAN have been linked to abnormal serum lipid levels, and variants near PPP1R3B and GCKR have been shown to affect glycemic traits [23, 24] . These pathways have been found to play an important role in the progression of liver damage among patients with NAFLD and NASH [23, 24] . Only rs738409 (I148 M) in PNPLA3 has been previously investigated in a sample of adults in Mexico.
Subjects and methods
The Mexican Health Worker Cohort Study (MHWCS) is a long-term study of workers from two organizations located in Cuernavaca, Mexico, the Mexican Institute of Social Security and the National Institute of Public Health, and their immediate family members. From 2004 to 2006 (Wave 1), approximately 4000 health workers between 20 and 85 years of age were enrolled in the MHWCS, and 1026 of these participants were followed-up during 2011-2013 (Wave 2). Study participants completed several self-reported questionnaires that collected information about demographics, overall health status, and behavioral factors (eg. diet, physical activity, alcohol consumption), at each follow-up period. They also underwent a complete physical examination and blood tests following an overnight fast, including transaminase levels (ALT and AST), cholesterol (total, HDL and LDL), triglycerides, glucose, body fat proportion (DEXA), etc. at every follow-up phase. During Wave 2, the participants also provided a blood sample for genetic testing, after an overnight fast. Study activities, such as clinical procedures, data coding and entry, and participant follow-up practices, have been standardized and validated [28, 29] .
A nested case-control study was conducted using a sample of 207 cases of NAFLD and 534 healthy controls from the MHWCS. Controls were selected from participants in the MHWCS who had a minimum of two consecutive normal alanine aminotranserase levels (ALT B40 UI/L) results in both Wave 1 (2004 Wave 1 ( -2006 and Wave 2 (2011 Wave 2 ( -2013 . The cases of NAFLD were confirmed by ultrasound to identify the accumulation of fat in the liver. Participants who self-reported as heavy or binge drinkers, were infected with HBV or HCV, or had a prior liver disease diagnosis were excluded from this study.
Genotyping of SNPs in candidate genes
A commercial isolation kit (QIAGEN systems Inc., Valencia, CA) was used to extract the genomic DNA from the peripheral blood of the study participants. Commercial predesigned TaqMan Probes in a StepOne Plus RT PCR system (Applied Biosystems, Foster City, CA, USA) were used to genotype the following nine SNPs: rs738409 (PNPLA3), rs12137855 (LYPLAL1), rs4240624 (PPP1R3B), rs780094 (GCKR), rs2228603 (NCAN), rs2943634 and rs2972146 (IRS1), rs1801282 (PPARG), and rs767870 (ADIPOR2), which have been examined in various studies [21] [22] [23] [24] [25] [26] , and associated in Hispanic and/or Mexican-American populations. The call rate was greater than 97 % for the SNPs that were tested and we did not observe any discordant genotypes in 20 % of duplicate samples. Since the Mexican-Mestizo population is admixed, we used ancestry informative markers (AIMs) to rule out false associations due to population stratification. The GoldenGate BeadArray (Illumina) was used to genotype a set of 96 AIMs distributed across the genome. These AIMs have been validated in other studies of the Mexican population to primarily distinguish between the American, European and African populations [30, 31] .
Clinical and anthropometric measurements
Body mass index (BMI) and the following clinical measures: cholesterol (total, HDL and LDL), and triglycerides, were examined as part of this study. Subjects were classified based on BMI according to the guidelines established by the National Heart, Lung and Blood Institute: normal weight (18.5-24.9 kg/m 2 ), overweight (25.0-29.9 kg/m 2 ), and obesity (C30.0 kg/m 2 ) [32] .
Statistical analyses
Student's t tests and Pearson Chi square tests were used to evaluate the socio-demographic and clinical differences between the cases and controls. For each SNP, maximum likelihood estimates of allele frequencies were tested for departures from Hardy-Weinberg Proportions using the Chi square goodness of fit test among the 534 study controls. In a case-control study design, controls are meant to be representative of the general population, under a rare disease assumption. If genotypes are associated with different disease risks, then the genotypes of cases may not be in HWE.
Our primary analysis was to determine the individual association between each SNP and persistently elevated aminotransferase levels, using an additive model. Unconditional univariate and multivariate logistic regression analyses were used to calculate the crude and adjusted odds ratios (ORs) for risk of persistently elevated aminotransferase levels, and their 95 % confidence intervals (CIs). Age, sex, BMI, and ancestry were included as potential confounder variables in the multivariate logistic regression models that examined the association between case-control status and genotype. Logistic regression has considerable flexibility in hypothesis testing and allows for the adjustment of covariates or computation of interactions between genotypes and other environmental exposures. To correct for multiple testing and address the problem of Familywise Type I Error, we applied the Bonferroni correction method [33] by dividing a by the number of genes/SNPs we examined (0.05/8), which resulted in a significance threshold of P = 0.006. Multiple linear regression models were used to explore the interaction between BMI and selected SNPs on aminotransferase levels, adjusting for the aforementioned potential confounders.
Quanto1.1 software was used to calculate statistical power for a significance level of 0.006 and MAF of 4.5-65 % in 207 cases and 508 controls, considering a minimum power of 80 % to detect differences in ALT levels, under an additive model. Stata 11 was used for the statistical analyses and a two-sided P value of \0.05 was considered to be statistically significant.
The study protocol and informed consent forms were approved by the ethics committees of all participating institutions, and signed informed consent was provided by all participants. The research activities were conducted in accordance with the principles outlined in the Declaration of Helsinki. Additionally, we followed the Strengthening the Reporting of Genetic Association Studies guidelines to describe the study group selection and genetic association analysis [34] .
Results

Study sample characteristics
The participants included 207 cases and 534 controls, of which 35.7 % and 21.9 % were males, respectively. The mean age of the study subjects was 47.7 ± 11.6 and 50.0 ± 13.5 years, and BMI was 29.1 ± 4.6 and 26.2 ± 4.4 kg/m 2 in case and controls, respectively. The demographic and clinical data that were observed among the cases and controls at baseline are presented in Table 1 . No statistically significant differences were found between cases and controls in terms of education, hypertension, total cholesterol and LDL cholesterol (P [ 0.05). Cases were significantly more likely to be male, younger, have a greater BMI, type 2 diabetes, have lower HDL cholesterol, higher triglyceride, ALT and AST levels, and an ALT/ALT [1 and [2, as compared to the controls (P \ 0.05).
Association between SNPs and risk of persistent elevated aminotransferase levels All minor allele frequencies (MAFs) that were observed in this study are comparable to those found in the MXL (Mexican Ancestry in Los Angeles, California) samples from the 1000 genomes project. One of the nine SNPs (rs4240624, PPP1R3B gene) had a substantially lower MAF among the CEU samples (6 vs 30, respectively), whereas the MAF for the rs2228603 SNP (NCAN gene) was lower in the 1000 genomes-MXL samples and in the controls than among CEU (2 vs 9, respectively). The genotype and allele frequency distributions observed for all SNPs did not differ from Hardy-Weinberg equilibrium among the controls (Table 2) . Table 3 reports the association between nine SNPs and risk of persistently elevated ALT levels, along with their adjusted ORs. Our unadjusted results indicate that the rs738409 (PNPLA3), rs12137855 (LYPLAL1), rs4240624 (PPP1R3B), rs780094 (GCKR), and rs2228603 (NCAN) SNPs are associated with persistently elevated aminotransferase levels. After adjusting for age, sex, BMI, type 2 . We also observed a trend to association between LYPLAL1 rs12137855 and persistently elevated aminotransferase levels (P = 0.022 adjusted for age, sex, type 2 diabetes, and BMI). After applying a Bonferroni correction using a P value threshold of 0.006, the only associations that remained significant were the PNPLA3 rs738409 SNP recessive model (P = 0.003) and the P for trend (P = 0.0052). (Table 3) .
Interaction between selected SNPs, BMI, and risk of persistent elevated aminotransferase levels
The PNPLA3 M148 M genotype was significantly more common among the cases in the total sample (P = 0.005) and among overweight/obese participants (P = 0.008). After stratification by sex, the association between the M148 M genotype and elevated ALT levels remained significant among females (P = 0.031). The presence of elevated ALT or AST levels was also greater among female M148 M carriers (P = 0.004), although sex differences were only significant in the total sample and among overweight/obese females ( Table 4) . The homozygous TT LYPLAL1 rs12137855 genotype was more common among cases in the total sample and among the overweight/obese, than the homozygous CC genotype (P = 0.066 and 0.021, respectively). This genotype was associated with elevated ALT in the total sample (P = 0.046) and among overweight/obese participants (P = 0.033). Additionally, the LYPLAL1 T risk allele was associated with elevated ALT or AST levels in the total sample and among the overweight/obese (P = 0.020 and 0.009, respectively) (Supplementary Table 1) .
Participants with the PPP1R3B G allele also had higher mean ALT levels than those with the A allele (42.1 vs 28.7, respectively, P = 0.056). The PPP1R3B risk allele was also associated with elevated ALT or AST levels in the overweight/ obese group and among the overweight/obese females (P = 0.035 and 0.042, respectively) (Supplementary Table 2) .
Among the total sample, we observed that participants with the GCKR heterozygous TC genotype were more likely to have an ALT or AST level C40 U/L (P = 0.052), and this was also the case among females (P = 0.022). A higher mean ALT level was observed among normal weight males with the GCKR T risk allele than those with the C allele (28.3 vs 19.9, respectively). We also observed differences in the proportion of participants with ALT or AST levels C40 U/L among overweight or obese females with the T risk allele and those with the C allele (P = 0.011), as well as among all overweight/obese participants (P = 0.034) (Supplementary Table 3 ).
Discussion
Our findings indicate an association between the PNPLA3 ''G'' allele of rs738409 and persistently elevated transaminase levels in a sample of Mexican adults from central Table 3 continued Mexico. Population structure of this admixed sample has no obvious effects on this association. These results support other studies that also report a higher prevalence of the PNPLA3 ''G'' allele among Mexican-Americans, MexicanMestizo and Mexican indigenous populations [21, 25] and adds to the evidence of an important determinant of interindividual and ethnicity-related variations in elevated ALT levels [35, 36] . We found that among overweight or obese women, the PNPLA3 ''G'', GCKR ''T'', and PPP1R3B ''G'' alleles were significantly related to persistently elevated ALT or AST levels. Although the proportion of obese or overweight males with elevated ALT levels was greater among those with the M148 M genotype, the association was only found to be significant among females. Additionally, the significant associations observed between elevated aminotransferase levels and the PNPLA3, LYPLAL1, PPP1R3B, and the GCKR risk alleles were greater in females, even though males were consistently found to have higher mean ALT levels. The lack of significance observed among males could be explained in part by the lower percentage of males in the study sample (36 %), as compared to females (66 %). We did not find an association between the IRS1, PPARG, and ADIPOR2 SNPs, which were previously associated with NAFLD in European populations. Potential reasons for this lack of association are that phenotype was not included in this The analyses with the total population were additionally adjusted for body mass index * Remain significant after a Bonferroni correction using a P value threshold of 0.006 study, racial/ethnic differences, and insufficient sample size. While the environmental risk factors for NAFLD and NASH are well known, less is understood about the genetic basis of hepatic steatosis. Even less is known about the genetic factors that contribute to liver disease susceptibility among Mexicans and other Latino populations, despite the disproportionate burden of liver cancer among this group [37] [38] [39] . To date, there is scarce information about the link between specific candidate genes and the development of NAFLD and NASH in Latino populations [25, [40] [41] [42] . A study by Hernaez et al. used data from the National Health and Nutrition Examination Survey (NHANES) III to investigate the association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and NCAN (rs2228603) with hepatic steatosis among whites, blacks and Mexican-Americans. They found that only the G allele rs73849 in PNPLA3 was significantly associated with hepatic steatosis and increased levels of ALT in Mexican-Americans [26] . Further studies with Latinos are needed to elucidate the role of specific SNPs in NAFLD and NASH susceptibility.
To the extent that elevated ALT or AST levels could be indicative of sub-clinical liver inflammation, our findings suggest that the presence of the PNPLA3, LYPLAL1, PPP1R3B, or GCKR risk alleles among Mexicans who are overweight or obese, could lead to a greater risk of developing chronic liver disease. In 2013, cirrhosis and other forms of chronic liver disease were the fifth leading cause of general mortality in Mexico [43] , and in 2008, chronic liver disease was the second cause of deaths in the 15-64 year age group [44] . The prevalence of steatohepatitis and cirrhosis in the US is higher among Latinos (45 %), than among whites (33 %) or African Americans (24 %) [4] . In 2013, chronic liver disease was the sixth leading cause of death for all U.S. Latinos, and the third leading cause of death for Latino males, ages 55-64 [45] . Although this research was conducted with adults in Mexico, our results may have implications for MexicanAmericans in the US, since prior studies have reported that ALT levels are generally higher in Mexican-American adults than among other races/ethnicities [5, 19, 46] .
Our study has several limitations. First, the MHWCS is not a population-based sample and the participants are predominantly female (75 %). Subjects are mainly health workers, who are probably better educated and healthier than the general population, which could bias our results towards the null. The MHWCS participants are likely representative of employed, middle-class, urban adults from central Mexico, which corresponds to an estimated 34 % of the population [47] . Second, the SNPs we examined were selected from previous reports based on populations that were predominantly European, and thus other SNPs in these genes could be associated with persistently elevated transaminase levels in our population. Third, our study was conducted with Mexicans, and does not include other Latino groups. Thus, our results might not be generalizable to other Latino groups due to the heterogeneity of health status among Latinos. Fourth, although histology is considered the ''gold standard'' to diagnose and stage NAFLD, we defined NAFLD cases as non-or moderate drinkers with least two elevated ALT or AST results and an ultrasound that identified liver fat. However, our results should be interpreted with caution since some studies have found that up to 75 % of patients with hepatic steatosis can have normal ALT and AST levels [4] , and there might also be misclassification bias if some participants reported that they were not drinkers when in fact they were. Additionally, ultrasonography is unable to detect liver fat below a threshold of 30 % [1] , and it cannot detect inflammation or fibrosis, which can indicate more advanced phases of NAFLD [48, 49] . Finally, the failure to observe an association between the LYPLAL1, PPP1R3B, GCKR, NCAN, IRS1, PPARG and ADIPOR2 SNPs, and elevated ALT levels in our population could be attributed to a relatively small sample size, which resulted in limited statistical power. In order to replicate the previously observed association of these SNPs with ALT levels, considering a rank of MAF of 0.02 for the NCAN SNP to 0.32 for the GCKR SNP, a total of 1769 cases and 4422 controls would be needed to achieve at least 80 % statistical power to detect a significant association. Taking into account the genotype frequencies we observed and our sample size, we had a statistical power of 80 % (at a = 0.006) to detect a genetic risk (odds ratio) of 1.6 for elevated ALT levels in additive mode of inheritance (Quanto software version 1.2.2) for rs738409 of the PNPLA3 gene. Despite these limitations, this study is the first to examine these nine SNPs in a sample of Mexican adults.
In conclusion, our results confirm that the risk allele of PNPLA3 rs738409 is associated with persistently elevated ALT or AST levels, after adjusting for age, sex and BMI. We also found that the LYPLAL1 (rs12137855) SNP is associated with elevated ALT levels among overweight/ obese individuals, while the PPP1R3B (rs4240624) and GCKR (rs780094) SNPs are associated with elevated ALT or AST levels among overweight/obese females. Our findings suggest that among Mexicans, the PNPLA3, LYPLAL1, PPP1R3B, and GCKR polymorphisms may be associated with a greater risk of developing chronic liver disease in overweight/obese adults. Recently, a genetic risk score constructed with the PNPLA3, LYPLAL1, PPP1R3B, and GCKR polymorphisms was associated with a higher hepatic triglyceride content and ALT levels in Mexican Mestizo subjects with severe obesity [50] . Based on previously reported studies, our replication results suggest that the PNPLA3, LYPLAL1, PPP1R3B, and GCKR SNPs may be useful genetic markers to help identify sub-clinical liver disease among Mexicans who are overweight/obese. This is particularly relevant because approximately 68 % of males and 74 % of females in Mexico are overweight or obese, and by 2050 these estimates are expected to increase to 88-91 %, respectively [51] . Further fine mapping and GWAS confirmation studies are needed with a significantly larger sample of Mexicans to determine the main associated variants in this high-risk population.
